Akira Jing Liu

Akira Jing Liu has a wealth of work experience. In 2009, they began as a Biology Group Researcher at Beijing Hanmi Pharmaceutical Co., Ltd. (Hanmi Group member). In 2013, they moved to Sanofi as a Strategy, Science Policy & External Innovation in Asia Pacific office. In 2014, they became a Strategic Planning Executive at Ethypharm. In 2017, they moved to Qianzhan Asset Management as an Investment Manager focus on Biotech. In 2018, they became a Board Member at Capella Therapeutics. In 2019, they joined Genenta Science as a Board Observer. In 2020, they moved to AnHeart Therapeutics as a Senior Director of Business Development and a Director of Business Development. In 2021, they became a Sr. Director of Business Development at Innovent Biologics. Most recently, in 2023, they joined Duality Biologics as an ED, Business Development.

Akira Jing Liu attended Jilin University from 2002 to 2009, where they earned a Master of Medicine in Immunology. They then attended Keck Graduate Institute from 2012 to 2014, earning a Master of Bioscience in Business of Bioscience.